ABSTRACT
INTRODUCTION
Distal sensory polyneuropathy (DSP) can be a result of long-term human immunodeficiency virus (HIV) infection or toxicity associated with certain antiretroviral drugs, specifically stavudine, didanosine, and zalcitabine. 1 The HIV-DSP may include symptoms such as pain, numbness, and paresthesias and adversely affect quality of life (QOL), sleep, and lower limb function. Pain is a frequent occurrence and often does not respond completely to usual analgesic medications. 2, 3 In a review of 37 studies, Ghosh et al 4 found reports of prevalence of DSP varied from 1.2% to 69.4% in individuals with HIV disease. The complexity of the disease and the lack of standardized diagnostic criteria may contribute to the variance in reported prevalence between studies. 4 Age, lower CD4 nadir, current antiretroviral therapy (ART) use, and past dideoynucleoside analogue antiretrovirals ("D-drugs") use were all found to be risk factors for HIV-DSP. 5 These drugs have been recognized as neurotoxic, leading to the use of alternative pharmacologic approaches; however, stavudine continues to be widely used in first-line therapy in developing countries due to its low cost and widespread availability. 5 Recent research has shown statistically significant negative correlations between neuropathic pain and subjective report of daily function, employment, and QOL as assessed by the Medical Outcome Survey (MOS)-HIV. 5 In addition, neuropathic pain may correlate with other impairments and functional limitations experienced during the course of living with HIV disease.
According to O'Brien, 6, 7 persons living with HIV experience disability that is defined as a multidimensional, episodic state consisting of unpredictable periods of good health and poor health. Disability for people living with HIV encompasses symptoms, impairments, difficulties carrying out day-to-day activities, and challenges to social inclusion all of which vary over time. 8 The HIV-DSP can alter function and QOL; yet few studies have measured the functional impact on this condition.
Diagnostic screening tools and functional assessment measures have qualified and quantified neuropathy symptoms and lower limb function in people who have peripheral neuropathy. 9 Diagnostic clinical screening tools have been developed to assess HIV-related DSP. 10 However, few tools for measurement of function have been tested for use in people with HIV-related DSP. 8 The purpose of this review was to describe existing diagnostic screening tools for HIV-related DSP, and explore functional assessment measures that might be of benefit for this population. dated for use in the HIV population. Through PubMed, screening was based on title and abstract, 749 articles were found when searching HIV peripheral neuropathy and results were narrowed to 186 articles when the term, sensory was added. The search was further limited with the addition of the term, screen that yielded a total of 12 articles. These articles were screened on content, with 5 resulting in relevant articles regarding assessment tools for use with HIV-related DSP (Figure 1 ). The same search was conducted in Biological Sciences database using the same sequence with HIV peripheral neuropathy resulting in 1315 articles. The number of results included 316 articles using the term, sensory followed by the term, screen resulting in 15 total articles. Of those 15 articles, the same 5 articles noted in PubMed were relevant. Finally, a cumulative search on EbscoHost using Medline, CINAHL, Health Source and Academic Search Premier was conducted using the same key terms: HIV peripheral neuropathy (298), sensory (81), and screen with a final result in 7 articles. Of the 7 articles reviewed, 3 included pertinent information and were the same as previous database acquisitions.
RESULTS
The 5 articles from the search described the use of the Brief Peripheral Neuropathy Screen (BPNS), the Total Neuropathy Score (TNS), the Subjective Peripheral Neuropathy Screen (SPNS), the Neuropathy Screening Scale (NSS), and the Single Question Neuropathy Screen (SQNS). 10 . These 5 assessment tools and their clinometric properties are summarized in Table 1 .
Total Neuropathy Score
The TNS was originally validated in patients with chemotherapy induced neuropathy. The TNS has also been used for patients with diabetic neuropathy. In a cohort of patients with advanced HIV disease, the TNS measured DSP and was found to be relatively stable over 48 weeks. 11 The TNS provides a single measure to quantify neuropathy by combining information obtained from a grading scale of symptoms, signs, nerve conduction studies, and quantitative sensory tests. Each parameter is obtained separately from the examiner or from nerve conduction studies and is quantified into a total score based upon its specific rank as described in the TNS. For example, a subject without sensory symptoms will rank a '0,' while a subject with sensory symptoms into the toes or fingers will rank a '1.' Each parameter is given a rank and quantified to give a total score. Parameters include sensory symptoms, motor symptoms, autonomic symptoms, pin sensation, vibration sensibility, strength, tendon reflexes, vibration sensation (quantitative sensory test vibration), sural nerve amplitude, and peroneal nerve amplitude. Cornblath et al 9 measured the inter-and intrarater reliability and validity of the TNS and its subscales against the NSS and the Neurological Impairment Score (NIS). The interand intrarater reliability of the TNS was determined to be 0.966 and 0.986 respectively. 9 The cross-sectional validation study of the TNS showed excellent correlations among all measures of neuropathy. 9 
Subjective Peripheral Neuropathy Screen
The SPNS is a self-reported questionnaire to determine the presence and severity of the following 3 symptom categories in the upper and lower extremities: 'pain, aching, and burning,' 'pins and needles' or paresthesias, and 'numbness.' The symptoms are rated on a scale of 0 (no symptoms) to 10 (severe symptoms). The scale is used to screen patients for sensory problems that may potentially be neuropathy; it is used by many clinicians as a primary way to assess the presence and severity of peripheral neuropathy syndrome. Research shows a positive relationship between neurological exam findings and the SPNS score, with numbness in feet and legs having the highest efficiency in correctly classifying peripheral neuropathy. 12 The SPNS was established through a group of neurologists with specialty knowledge of the symptoms of DSP, thereby establishing the content validity of this assessment tool. Construct validity was found using known groups since there was an observed difference in the results of the scale between the HIV positive DSP group and the HIV positive control group. Criterion-related validity was supported with the neurology graded exam and vibration sensation test. The SPNS was found to be reliable using Cronbach's alpha test (internal consistency = 0.86). The SPNS was also found to be specific (84%) but not sensitive (51%). This scale is quick to administer and there is a high correlation between DSP symptoms as reported in the SPNS screen and a neurologic screen. Although there are some problems with the sensitivity of the scale, the SPNS is an effective tool to use in the clinic to assess DSP.
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Brief Peripheral Neuropathy Screen
The BPNS is a validated screening tool that provides a measurement of the severity of peripheral neuropathy. 13 The subjective information includes patients' description of their symptoms, and the intensity of their pain. These symptoms include: pain, aching or burning in feet or legs, 'pins and needles' in feet or legs, and numbness in feet or legs. The objective measures include patients' perception of vibration of 128 Hz at the great toe, and deep tendon reflex at the Achilles tendon.
The BPNS can be administered in less than 10 minutes in almost any clinical setting. The screen allows clinicians to diagnose HIV-DSP. When a patient exhibits one or more symptoms specified in the BPNS, and also exhibits either diminished ankle reflex or reduced vibration sense at the great toe, they are diagnosed with HIV-DSP. The BPNS shows a sensitivity of 49% (95% CI 37% -65%), a specificity of 88% (95% CI 82% -91%), and a correct diagnosis 78% of the time. 14 In a study by Simpson, 11 as compared with the TNS, the BPNS had relatively lower sensitivity and higher specificity for the diagnosis of DSP. Neuropathy Severity Score The NSS is a novel screening tool derived from the BPNS, SPNS, SQNS, and the physical function scale from MOS-HIV. 10 This tool combines subjective information, objective information, and a functional level scale consisting of 3 questions. 10 Part A of the NSS is a subjective patient report of symptoms including pain, aching, or burning in feet or legs; 'pins and needles' in feet or legs; and numbness (lack of feeling in feet or legs). The patient reports the severity of these symptoms on a scale of 0-10. 10 Part B asks the patient if the symptoms in Part A limit their ability to participate in the following domains: vigorous activities, moderate activities, climbing one flight of stairs, and walking 50 meters. They report their limitations as either 'yes, limited a lot,' 'yes, limited a little,' or 'no, not limited at all. ' 10 Part C is objective and measures the patients' ankle reflexes as absent, decreased, normal, increased, or clonus. 10 This is the only instrument that begins the inquiry of function in addition to the examination of DSP.
The NSS was tested for reliability and validity in a study of 30 HIV positive patients from a Kenyan HIV-care clinic. A convenience sample was used, and the tests were administered by nonphysician health care workers. The results showed a sensitivity of 66.7% (95% CI [29, 104] ) and a specificity of 91.7% (95% CI[81, 103)].
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Single Question Neuropathy Screen
The SQNS is used routinely in Zambia for those commencing antiretroviral therapy in publicly funded clinics. The question: "Do you experience tingling, burning, or numbness in your feet or hands" was assessed against the BPNS in detecting HIV associated DSP. The SQNS was found to be both sensitive (95.7%) and specific (80.0%) with 88.2% positive predictive value and 92.3% negative predictive value. Age, geographical location, gender, and stage were found to be independent of the results of the SQNS within this study. This single question screen is used in Zambia, but may be a clinically meaningful tool for identifying HIV-DSP pending future research.
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DISCUSSION
The lack of consensus in reference to a universally accepted definition of HIV-DSP has led to the use of multiple screening tools. These 5 tools described in this review assess how altered neurological status of the lower extremity may affect sensation and perception of pain. These screening tools differ greatly in their psychometric properties, the number of items they contain, and the dimensions of HIV-DSP (eg, physical, functional, and affective). Because of this, these screening tools can be used together to assess multiple aspects of health and neurological function. While the SPNS uses purely subjective information to assess the severity of neuropathy symptoms, the TNS, BPNS, and SQNS include a collection of subjective information about pain and objective information about the integrity of peripheral nerves. Only the NSS asks questions regarding function but does not provide the degree of functional disability during the course of HIV-DSP. For the clinician assessing the presence of HIV-DSP, determining which one or a combination of these scales would be the 'gold standard' for qualifying and quantifying the symptoms of HIV-DSP may provide greater insight into clinical decision making for this population.
To create a more comprehensive assessment of the effects of HIV-DSP, use of more extensive function-based measurement tools should be considered. Of the 5 neuropathy-screening scales we described, only the NSS specifically asks functional-based questions. More extensive objective measurement of function in patients with HIV-related DSP would allow the clinician to be able to confirm their need for further therapy. Further research is needed to explore objective measurement of function in individuals with HIV-associated DSP. Self-reported outcome measures such as the Lower Extremity Functional Scale (LEFS) 16 and the Lower Limb Functional Index (LLFI) 17 should be considered for validation in the HIV-related DSP patient population. The LEFS is used in outpatient orthopedics to measure initial function, ongoing progress, and outcomes. 16 The LEFS has been tested for validity and used to assess nerve related dysfunctions such as sensory deficits, neuropathic pain, and DSP. 17 Gabel et al 18 compared the validity and reliability of a newer assessment tool called the Lower Limb Functional Index (LLFI) to that of the LEFS and found that the LLFI demonstrated equivalent or superior clinometric properties compared to the LEFS. While the LLFI has not been tested in nerve related dysfunction, it may serve as an alternate tool to the LEFS. Therefore, the LEFS and the LLFI may have potential utility in the HIV-DSP population to objectively measure the functional ability of HIV-DSP patients. .
Recent research has reported compromised quality of life in people living with HIV disease; yet there are few studies that address specific functional concerns as a result of HIV-DSP. 4 This makes it difficult for clinicians to track progress in these individuals, especially considering the cyclical tendencies of this disease. 6 To satisfy the need for functional assessment in this population; the LEFS and the LLFI are suggested tools requiring additional research and may complement the 5 clinical tools for HIV-DSP.
CONCLUSION
Clinicians should consider routine use of assessment tools for HIV-DSP. The TNS, SPNS, BPNS, SQNS, and NSS may assist in this differential diagnosis. Though these tools have been validated in the HIV population, only the NSS has a global functional component. In order to enhance clinicians' ability to diagnose and treat individuals with HIV-DSP, further research is needed to validate a tool to capture more specific functional deficits of these patients. By including the domain of function in assessment of individuals with HIV-DSP, we can begin to quantify changes over time and determine the impact of rehabilitation interventions for this population.
